Bei Jing Ri Bao Ke Hu Duan·2025-08-21 11:02Core Insights - The article highlights the profitability achievements of Beijing-based innovative pharmaceutical companies, particularly Baijiahong and Nocare, marking a significant milestone in their development journey [1][2]. Group 1: Company Performance - Baijiahong reported a net profit of 450 million yuan in the first half of the year, achieving profitability for the first time [1][3]. - Nocare achieved a net profit of 18 million yuan in the first quarter, marking its first quarterly profit, with a significant reduction in net loss to 36 million yuan in the first half of the year [4]. Group 2: Product Sales and Market Expansion - Baijiahong's innovative drug, Zebutinib, generated global sales of 12.527 billion yuan in the first half, a year-on-year increase of 56.2%, with notable growth in the U.S. (51.7%) and Europe (81.4%) [3]. - The sales of another cancer drug, Trelatuzumab, reached 2.643 billion yuan, reflecting a 20.6% increase, driven by new indications approved in China [3][4]. Group 3: R&D and Future Prospects - Baijiahong has established a new R&D center in Changping, covering over 47,000 square meters and equipped with advanced laboratories, supporting the development of over 40 products in clinical and commercialization stages [2][3]. - Nocare is expanding its pipeline with its core product, Obutinib, which is also being tested for autoimmune diseases, potentially unlocking new market opportunities [4].